International Patent: MHC II EXPRESSION AS A PREDICTIVE BIOMARKER FOR CD4 DEPLETION ANTICANCER IMMUNOTHERAPY

GENEVA, Aug. 14 -- CEDARS-SINAI MEDICAL CENTER filed a patent application (US2026/014087) for “MHC II EXPRESSION AS A PREDICTIVE BIOMARKER FOR CD4 DEPLETION ANTICANCER IMMUNOTHERAPY”. With publication no. WO/2026/169870, here are the other details related to the patent application:

Kind: Initial Publication with ISR [A1]

IPC: A61K 39/395

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Disclaimer: Curated by HT Syndication....